• Anagliptin Vasorelaxation: Kv Channels and SERCA

  2026-08-25

  This rabbit-aorta study shows that anagliptin relaxes phenylephrine-contracted vascular smooth muscle through pharmacologically supported involvement of voltage-dependent K+ channels and the SERCA pump. The findings extend research on DPP-4 inhibition mechanism toward direct vascular physiology while indicating that the response does not require the endothelium or canonical cAMP/PKA and cGMP/PKG signaling.

• Moxidectin: From Dewormer to Assay Tool

  2026-08-25

  Moxidectin is a macrocyclic lactone anthelmintic with established veterinary utility and emerging value in antifungal combination research. This article explains how its distinct ergosterol-centered activity can guide better Candida assay design, compound handling, and translational interpretation.

• Ertugliflozin (PF-04971729) Research Workflows

  2026-08-24

  Build selective renal glucose transport assays, dose-response studies, and translational inflammation models with PF-04971729. This practical guide connects assay design and troubleshooting to the cardiovascular evidence surrounding ertugliflozin without treating clinical outcomes as a substitute for bench validation.

• PAD4-IN-2 TFA: Tumor-Targeted NET Research

  2026-08-23

  PAD4-IN-2 TFA, also known as Compound 5i TFA, links tumor-directed uptake with PAD4–H3cit–NET pathway analysis. This guide shows how to use it in migration, citrullination, NET, immune-profiling, and in vivo tumor workflows while separating evidence-backed findings from assay optimization recommendations.

• DIDS: Reliable Assay Design with SKU B7675

  2026-08-22

  DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid), SKU B7675, can strengthen mechanistic interpretation in cell viability, cytotoxicity, and stress-survival experiments when paired with appropriate controls. This guide addresses assay compatibility, concentration selection, data interpretation, and practical vendor evaluation using product data and a peer-reviewed metastasis study.

• VERTIS CV: Ertugliflozin Cardiovascular Outcomes

  2026-08-21

  The VERTIS CV trial tested whether ertugliflozin preserved cardiovascular safety in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Ertugliflozin was noninferior to placebo for major adverse cardiovascular events, while reductions in heart-failure hospitalization and renal outcomes were numerically favorable but not statistically superior.

• Ertugliflozin (PF-04971729) in Translational Research

  2026-08-21

  Ertugliflozin (PF-04971729) combines highly selective SGLT2-mediated glucose reabsorption inhibition with practical applications in renal transport, diabetes mellitus research, and neuro-metabolic models. This workflow-focused guide translates a rat Alzheimer’s disease study into reproducible dosing, biochemical, and troubleshooting strategies.

• Praeruptorin A, DMT1, and Doxorubicin Cardiomyopathy

  2026-08-20

  The reference study established a ferrous-ion-based high-throughput screening strategy to identify Praeruptorin A as a candidate ferroptosis inhibitor for doxorubicin-induced cardiomyopathy. Its experiments link reduced DMT1 expression and Fe²⁺ overload with protection of cardiomyocytes and mouse cardiac function, while also indicating that Praeruptorin A can enhance doxorubicin activity against MCF-7 breast cancer cells.

• Structure-Guided Proteomimetics Block SARS-CoV-2 Entry

  2026-08-20

  This study develops constrained proteomimetics that reproduce key structural elements of hACE2 and interfere with the SARS-CoV-2 Spike receptor-binding domain interaction. The lead construct, compound 28, combined selective target engagement with pseudovirus-entry inhibition, prolonged stability in lung epithelial models, and low epithelial permeability relevant to potential intranasal delivery.

• Anagliptin (SK-0403): From DPP-4 to Vascular Biology

  2026-08-19

  Anagliptin (SK-0403) offers translational researchers a way to connect incretin biology with direct vascular physiology. This article examines its DPP-4 inhibition mechanism, the evidence for Kv channel modulation and SERCA pump regulation, and practical strategies for advancing vasorelaxant mechanism research beyond a conventional product-page narrative.

• Talabostat mesylate (PT-100) for FAP Tumor Assays

  2026-08-19

  Talabostat mesylate, also known as PT-100, gives researchers a practical pharmacological tool for separating DPP4 and FAP biology in tumor, immune, and stromal models. This guide translates FAP-focused vascular research into reproducible workflows, control strategies, and troubleshooting steps without equating enzyme inhibition with direct antitumor efficacy.

• SHC-1 Inhibition and CFTR Surface Trafficking

  2026-08-18

  Barros and colleagues show that MAPK/SHC-1-dependent CFTR internalization is conserved across airway and intestinal epithelial models, but pharmacological SHC-1 inhibition increases surface CFTR only in CFBE cells. The study’s key contribution is its emphasis on cell-context dependence and unrelated plasma membrane controls when evaluating CFTR trafficking interventions.

• ARID1A-Dependent Resistance in Melanoma Multi-Omics

  2026-08-18

  This study integrates transcriptomic, protein-level, and signaling data to define how ARID1A loss rewires melanoma responses to BRAF/MAPK inhibition. Its identification of PRKD1, JUN, and NCK1 as resistance-associated network nodes provides a mechanistic framework for studying adaptive signaling, immune-evasion features, and therapeutic failure.

• Antipyrine in BBB Assays: Measuring Flux and Fate

  2026-08-17

  Antipyrine can strengthen blood-brain barrier assay interpretation when permeability, efflux, and intracellular recovery are analyzed together. This guide translates a 2025 surrogate BBB study into practical decisions for pharmacokinetic studies, dose preparation, and mass-balance control.

• ARCA Cy5 EGFP mRNA (5-moUTP): Assay Design

  2026-08-16

  ARCA Cy5 EGFP mRNA (5-moUTP) enables researchers to separate cellular uptake from productive translation in mammalian-cell delivery studies. This guide turns dual fluorescence into a rigorous framework for evaluating macrophage-targeted nanoparticles, localization, and transfection performance.

454 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page